ArticleScientific reports2026
Programmed cell death ligand 1(PD-L1) association in metastatic and non-metastatic oral squamous cell carcinoma: clinicopathologic and immunohistochemical study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral Squamous Cell Carcinoma (OSCC) is considered a highly immunosuppressive malignancy largely mediated by the Programmed Cell Death 1/Programmed Cell Death Ligand 1(PD-1/PD-L1) axis. The interaction between PD-L1 expressed on tumor cells and PD-1 receptors on T-cells results in T-cell dysfunction, exhaustion, and immune evasion within the tumor microenvironment. This study aimed to evaluate PD-L1 expression in primary non-metastatic OSCC, primary metastatic OSCC, and nodal metastatic OSCC, as well as to investigate its association with different available clinicopathological parameters. Immunohistochemical staining was performed to retrospectively evaluate PD-L1 expression in 30 archival paraffin-embedded OSCC specimens retrieved from the Department of Oral Pathology, Faculty of Dentistry, and the Oncology Center, Faculty of Medicine, Mansoura University. PD-L1 immunoreactivity was evaluated using a semi-quantitative scoring system based on both the staining intensity and the percentage of positively stained cells. The percentage of immunopositive cells was scored as stated: 0 (0%); 1 (< 25%); 2 (25-50%); 3 (50-75%); and 4 (> 75%). Staining intensity was graded as follows: (0 = negative); (1 = weak); (2 = moderate); and (3 = strong). A combined immunoreactivity score was calculated by adding the percentage and the intensity for each case (range 0-7). The final score was categorized as follows: 0 (negative); 1-3 (weak); 4-7 (strong). Statistical analysis was conducted to determine significant differences and correlations between PD-L1 expression and clinicopathological parameters using the Chi-square test, Monte Carlo test, one-way ANOVA, Student's t-test, and Fisher's exact test. The p-value < 0.05 was considered statistically significant. PD-L1 immunopositivity was detected in all OSCC cases (100%). A statistically significant difference was observed among the different studied groups (p < 0.001), with the strongest PD-L1 expression detected in both primary metastatic and nodal metastatic OSCC. Strong PD-L1 expression showed a significant association with patient age (p = 0.024). Additionally, a significant correlation was identified between PD-L1 expression and the depth of tumor invasion (p < 0.001). PD-L1 expression may have a potential role in tumor progression of OSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.